Targeting CD38 Enzymatic Function in Antibody-Driven Immunotherapy for Multiple Myeloma: Insights from Basic Research
Clinical Scorecard: Targeting CD38 Enzymatic Function in Antibody-Driven Immunotherapy for Multiple Myeloma: Insights from Basic Research
At a Glance
| Category | Detail |
|---|
| Condition | Multiple Myeloma (MM) |
| Key Mechanisms | CD38 enzymatic activity contributes to adenosinergic metabolism, promoting immune suppression. |
| Target Population | Patients with Multiple Myeloma, particularly those receiving CD38-targeted therapies. |
| Care Setting | Oncology, specifically in the treatment of hematologic malignancies. |
Key Highlights
- CD38-targeting mAbs (daratumumab and isatuximab) show antitumor activity but face resistance challenges.
- CD38 degrades NAD+ into ADPR, influencing adenosine production and immune suppression.
- Persistent adenosinergic signaling during therapy may contribute to immune evasion in MM.
Guideline-Based Recommendations
Diagnosis
- Utilize CD38 expression levels for diagnosis and monitoring of Multiple Myeloma.
Management
- Consider CD38-targeted monoclonal antibodies as part of the treatment regimen for MM.
Monitoring & Follow-up
- Monitor adenosine and its metabolites in patients undergoing CD38-targeted therapy.
Risks
- Be aware of potential therapeutic resistance due to sustained adenosinergic immunosuppression.
Patient & Prescribing Data
Patients diagnosed with Multiple Myeloma, particularly those with high CD38 expression.
Combining CD38-targeted therapies with agents that disrupt adenosinergic signaling may enhance treatment efficacy.
Clinical Best Practices
- Integrate monitoring of adenosinergic metabolites in treatment plans for MM.
- Explore combination therapies targeting both CD38 and adenosinergic pathways.
References
